10x Genomics, Inc. (TXG) Q1 2025 Earnings Call Transcript
10x Genomics, Inc. (NASDAQ:TXG ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Cassie Corneau – Senior Director, Investor Relations Serge Saxonov – Chief Executive Officer and Co-Founder Adam Taich – Chief Financial Officer Conference Call Participants Patrick Donnelly – Citi Kyle Mikson – Canaccord Genuity Madeline Mollman – Wolfe Research Matt Sykes – Goldman Sachs Kyle Boucher – TD Cowen Operator Ladies and gentlemen, thank you so much for standing by and welcome to 10x Genomics First Quarter 2025 Earnings Conference Call. Please note that this call is being recorded.
Compared to Estimates, 10x Genomics (TXG) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.50 per share a year ago.
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics: Lower Cost Innovation May Drive A Rebound
I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption, particularly in the biopharma sector, presenting significant revenue opportunities. Despite historical underperformance and high risk, TXG's leading technologies and potential market penetration justify holding the stock at current price levels.
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
On Wednesday, 10x Genomics Inc TXG reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of $(0.30).
10x Genomics, Inc. (TXG) Q4 2024 Earnings Call Transcript
10x Genomics, Inc. (NASDAQ:TXG ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Cassie Corneau - Senior Director, IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Adam Taich - CFO Conference Call Participants Dan Brennan - TD Cowen Patrick Donnelly - Citi Dan Arias - Stifel Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Tejas Savant - Morgan Stanley Dan Leonard - UBS Subbu Nambi - Guggenheim Securities Kyle Mikson - Canaccord Genuity Luke Sergott - Barclays Matt Larew - William Blair Matt Sykes - Goldman Sachs Michael Ryskin - Bank of America Operator Thank you for standing by. My name is [Prilla] and I will be your conference operator today.
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings
The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.41 per share a year ago.
Seeking Clues to 10x Genomics (TXG) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for 10x Genomics (TXG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results
10x Genomics, Inc. TXG reported a loss for the third quarter on Tuesday.
